

# Yan-Ping Mao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7672908/publications.pdf>

Version: 2024-02-01

143  
papers

7,604  
citations

81743

39  
h-index

62479

80  
g-index

143  
all docs

143  
docs citations

143  
times ranked

5960  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 818411.	2.2	1
2	Radiotherapy interruption due to holidays adversely affects the survival of patients with nasopharyngeal carcinoma: a joint analysis based on large-scale retrospective data and clinical trials. <i>Radiation Oncology</i> , 2022, 17, 36.	1.2	2
3	Long-Term Evaluation and Normal Tissue Complication Probability (NTCP) Models for Predicting Radiation-Induced Optic Neuropathy after Intensity-Modulated Radiation Therapy (IMRT) for Nasopharyngeal Carcinoma: A Large Retrospective Study in China. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	1
4	The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2022, , .	1.3	3
5	Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 479-490.	5.1	43
6	Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 46.	7.1	9
7	Necrosis in a Biomarker-driven, Phase 2 Trial of Adjuvant Apatinib in Patients of Nasopharyngeal Carcinoma with Residual Epstein-Barr Virus DNA after Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	4
8	A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	31
9	Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2420-2425.	0.8	44
10	A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 471-480.	3.0	17
11	Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. <i>Radiotherapy and Oncology</i> , 2021, 155, 56-64.	0.3	12
12	Development and validation of a web-based calculator to predict individualized conditional risk of site-specific recurrence in nasopharyngeal carcinoma: Analysis of 10,058 endemic cases. <i>Cancer Communications</i> , 2021, 41, 37-50.	3.7	7
13	Prognostic value of radiation interruption in different periods for nasopharyngeal carcinoma patients in the intensity-modulated radiation therapy era. <i>Cancer Medicine</i> , 2021, 10, 143-155.	1.3	3
14	Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. <i>Molecular Cancer</i> , 2021, 20, 14.	7.9	48
15	Evolving landscape and academic attitudes toward the controversies of global immunoncology trials. <i>International Journal of Cancer</i> , 2021, 149, 108-118.	2.3	5
16	An immune-related seven-lncRNA signature for head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 2268-2285.	1.3	14
17	Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems. <i>Radiotherapy and Oncology</i> , 2021, 157, 114-121.	0.3	32
18	The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. <i>Cancer Research and Treatment</i> , 2021, 53, 339-354.	1.3	63

#	ARTICLE	IF	CITATIONS
19	Normal tissue complication probability (NTCP) models for predicting temporal lobe injury after intensity-modulated radiotherapy in nasopharyngeal carcinoma: A large registry-based retrospective study from China. <i>Radiotherapy and Oncology</i> , 2021, 157, 99-105.	0.3	16
20	Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events. <i>BMC Cancer</i> , 2021, 21, 860.	1.1	2
21	Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 303-313.	6.3	98
22	Epstein-Barr virus microRNA BART10-3p promotes dedifferentiation and proliferation of nasopharyngeal carcinoma by targeting ALK7. <i>Experimental Biology and Medicine</i> , 2021, 246, 2618-2629.	1.1	5
23	Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2021, 122, 105555.	0.8	3
24	Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. <i>BMC Medicine</i> , 2021, 19, 193.	2.3	1
25	Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa. <i>European Radiology</i> , 2020, 30, 816-822.	2.3	23
26	Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. <i>Cell Research</i> , 2020, 30, 1024-1042.	5.7	182
27	New parameters of the 8th edition AJCC/UICC T category in nasopharyngeal carcinoma: Cervical vertebrae invasion and parotid gland invasion. <i>Clinical and Translational Medicine</i> , 2020, 10, e202.	1.7	1
28	Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology. , 2020, 8, e000334.		21
29	Prognostic value of MRI-determined cervical lymph node size in nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2020, 9, 7100-7106.	1.3	11
30	A New Model for Predicting Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 551255.	1.3	13
31	Plasma protein-based signature predicts distant metastasis and induction chemotherapy benefit in Nasopharyngeal Carcinoma. <i>Theranostics</i> , 2020, 10, 9767-9778.	4.6	14
32	The evolution of the nasopharyngeal carcinoma staging system over a 10-year period: implications for future revisions. <i>Chinese Medical Journal</i> , 2020, 133, 2044-2053.	0.9	3
33	A Nomogram Based on Serum Biomarkers and Clinical Characteristics to Predict Survival in Patients With Non-Metastatic Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 594363.	1.3	13
34	Evaluation of the National Comprehensive Cancer Network and European Society for Medical Oncology Nasopharyngeal Carcinoma Surveillance Guidelines. <i>Frontiers in Oncology</i> , 2020, 10, 119.	1.3	6
35	Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. <i>Oral Oncology</i> , 2020, 105, 104686.	0.8	14
36	The evolution of nasopharyngeal carcinoma staging. <i>British Journal of Radiology</i> , 2019, 92, 20190244.	1.0	73

#	ARTICLE	IF	CITATIONS
37	Thyroid doseâ€volume thresholds for the risk of radiationâ€related hypothyroidism in nasopharyngeal carcinoma treated with intensityâ€modulated radiotherapyâ€”A singleâ€institution study. <i>Cancer Medicine</i> , 2019, 8, 6887-6893.	1.3	19
38	Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. <i>New England Journal of Medicine</i> , 2019, 381, 1124-1135.	13.9	573
39	Prognostic impact of family history of cancer in Southern Chinese patients with esophageal squamous cell cancer. <i>Journal of Cancer</i> , 2019, 10, 1349-1357.	1.2	10
40	Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 355-361.	0.4	64
41	Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4271-4279.	3.2	234
42	The development and external validation of simplified T category classification for nasopharyngeal carcinoma to improve the prognostic value in the intensityâ€modulated radiotherapy era. <i>Cancer Medicine</i> , 2019, 8, 2213-2222.	1.3	11
43	Patterns of EBV-positive cervical lymph node involvement in head and neck cancer and implications for the management of nasopharyngeal carcinoma T0 classification. <i>Oral Oncology</i> , 2019, 91, 7-12.	0.8	16
44	Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual. <i>Oral Oncology</i> , 2019, 90, 23-29.	0.8	13
45	Evidence Underlying Recommendations and Payments from Industry to Authors of the National Comprehensive Cancer Network Guidelines. <i>Oncologist</i> , 2019, 24, 498-504.	1.9	7
46	Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data. <i>Frontiers in Oncology</i> , 2019, 9, 1343.	1.3	24
47	Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort. <i>Oral Oncology</i> , 2019, 89, 102-106.	0.8	16
48	Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Longâ€term results of phase 3 randomized controlled trial. <i>International Journal of Cancer</i> , 2019, 145, 295-305.	2.3	168
49	Panâ€cancer genomic analyses reveal prognostic and immunogenic features of the tumor melanogenic microenvironment across 14 solid cancer types. <i>Journal of Pineal Research</i> , 2019, 66, e12557.	3.4	26
50	Proposed modifications and incorporation of plasma Epsteinâ€Barr virus DNA improve the TNM staging system for Epsteinâ€Barr virusâ€related nasopharyngeal carcinoma. <i>Cancer</i> , 2019, 125, 79-89.	2.0	143
51	Role of sequential chemoradiotherapy in stage II and low-risk stage IIIâ€IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis. <i>Oral Oncology</i> , 2018, 78, 37-45.	0.8	20
52	Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. <i>Cancer Science</i> , 2018, 109, 751-763.	1.7	34
53	Antiâ€epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Cancer Science</i> , 2018, 109, 1609-1616.	1.7	11
54	Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis. <i>BMC Cancer</i> , 2018, 18, 323.	1.1	18

#	ARTICLE	IF	CITATIONS
55	Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis. <i>Oral Oncology</i> , 2018, 79, 40-46.	0.8	28
56	Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 382-393.	5.1	232
57	Cost-Effectiveness Analysis of Routine Magnetic Resonance Imaging in the Follow-Up of Patients With Nasopharyngeal Carcinoma After Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1382-1391.	0.4	8
58	Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life. <i>Radiotherapy and Oncology</i> , 2018, 126, 68-74.	0.3	74
59	A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry. <i>Cancer Research and Treatment</i> , 2018, 50, 324-334.	1.3	31
60	Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 363, k4226.	2.4	362
61	Long non-coding RNA DANCR stabilizes HIF-1 $\alpha$ and promotes metastasis by interacting with NF90/NF45 complex in nasopharyngeal carcinoma. <i>Theranostics</i> , 2018, 8, 5676-5689.	4.6	102
62	Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation. <i>Cancer Medicine</i> , 2018, 7, 5988-5998.	1.3	18
63	Prognostic value of nutritional risk screening 2002 scale in nasopharyngeal carcinoma: A large-scale cohort study. <i>Cancer Science</i> , 2018, 109, 1909-1919.	1.7	22
64	Feasibility of ipsilateral lower neck sparing irradiation for unilateral or bilateral neck node-negative nasopharyngeal carcinoma: systemic review and meta-analysis of 2, 521 patients. <i>Radiation Oncology</i> , 2018, 13, 141.	1.2	11
65	Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area. <i>Cancer Research and Treatment</i> , 2018, 50, 777-790.	1.3	8
66	Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis. <i>Chinese Journal of Cancer</i> , 2017, 36, 26.	4.9	30
67	Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. <i>European Journal of Cancer</i> , 2017, 75, 150-158.	1.3	115
68	Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area. <i>Cancer</i> , 2017, 123, 3540-3549.	2.0	47
69	Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy. <i>Oral Oncology</i> , 2017, 69, 99-107.	0.8	48
70	Socioeconomic factors and survival in patients with non-metastatic head and neck squamous cell carcinoma. <i>Cancer Science</i> , 2017, 108, 1253-1262.	1.7	33
71	Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 336-344.	2.3	15
72	Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2017, 123, 1643-1652.	2.0	48

#	ARTICLE	IF	CITATIONS
73	Use of pretreatment serum uric acid level to predict metastasis in locally advanced nasopharyngeal carcinoma. <i>Head and Neck</i> , 2017, 39, 492-497.	0.9	8
74	Impact of marital status at diagnosis on survival and its change over time between 1973 and 2012 in patients with nasopharyngeal carcinoma: a propensity score-matched analysis. <i>Cancer Medicine</i> , 2017, 6, 3040-3051.	1.3	26
75	Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A large-scale retrospective study. <i>Cancer Medicine</i> , 2017, 6, 2822-2831.	1.3	20
76	A network meta-analysis in comparing prophylactic treatments of radiotherapy-induced oral mucositis for patients with head and neck cancers receiving radiotherapy. <i>Oral Oncology</i> , 2017, 75, 89-94.	0.8	26
77	Refining the Role of Lymph Node Biopsy in Survival for Patients with Nasopharyngeal Carcinoma: Population-Based Study from the Surveillance Epidemiology and End-Results Registry. <i>Annals of Surgical Oncology</i> , 2017, 24, 2580-2587.	0.7	10
78	Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with NO-category nasopharyngeal carcinoma and enlarged neck lymph nodes. <i>Chinese Journal of Cancer</i> , 2017, 36, 32.	4.9	9
79	Decreased Overall and Cancer-Specific Mortality with Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy: Multivariate Competing Risk Analysis. <i>Journal of Cancer</i> , 2017, 8, 2587-2594.	1.2	6
80	Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy. <i>Journal of Cancer</i> , 2017, 8, 371-377.	1.2	25
81	Magnetic Resonance Imaging-Detected Tumor Residue after Intensity-Modulated Radiation Therapy and its Association with Post-Radiation Plasma Epstein-Barr Virus Deoxyribonucleic Acid in Nasopharyngeal Carcinoma. <i>Journal of Cancer</i> , 2017, 8, 861-869.	1.2	32
82	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. <i>Theranostics</i> , 2017, 7, 3585-3594.	4.6	214
83	Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institution. <i>Journal of Cancer</i> , 2017, 8, 1097-1102.	1.2	13
84	The Landscape of Clinical Trials Evaluating the Theranostic Role of PET Imaging in Oncology: Insights from an Analysis of ClinicalTrials.gov Database. <i>Theranostics</i> , 2017, 7, 390-399.	4.6	11
85	Patient- and treatment-related risk factors associated with neck muscle spasm in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy. <i>BMC Cancer</i> , 2017, 17, 788.	1.1	0
86	Significant value of 18F-FDG-PET/CT in diagnosing small cervical lymph node metastases in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>Chinese Journal of Cancer</i> , 2017, 36, 95.	4.9	25
87	Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 10594-10601.	0.8	5
88	Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. <i>Oncotarget</i> , 2016, 7, 24208-24216.	0.8	43
89	Circulating EBV DNA, Globulin and Nodal Size Predict Distant Metastasis after Intensity-Modulated Radiotherapy in Stage II Nasopharyngeal Carcinoma. <i>Journal of Cancer</i> , 2016, 7, 664-670.	1.2	27
90	Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy. <i>Scientific Reports</i> , 2016, 6, 22000.	1.6	58

#	ARTICLE	IF	CITATIONS
91	Publication status of contemporary oncology randomised controlled trials worldwide. <i>European Journal of Cancer</i> , 2016, 66, 17-25.	1.3	21
92	Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 1509-1520.	5.1	704
93	Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial. <i>Oncologist</i> , 2016, 21, 1369-1376.	1.9	50
94	Prognostic implications of dynamic serum lactate dehydrogenase assessments in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. <i>Scientific Reports</i> , 2016, 6, 22326.	1.6	24
95	Prognostic value of Diabetes in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy. <i>Scientific Reports</i> , 2016, 6, 22200.	1.6	7
96	The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy. <i>Scientific Reports</i> , 2016, 6, 24332.	1.6	22
97	The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma. <i>Scientific Reports</i> , 2016, 6, 24835.	1.6	52
98	Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. <i>Chinese Journal of Cancer</i> , 2016, 35, 103.	4.9	124
99	Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. <i>Tumor Biology</i> , 2016, 37, 4429-4438.	0.8	42
100	Neoadjuvant and Concurrent Chemotherapy Have Varied Impacts on the Prognosis of Patients with the Ascending and Descending Types of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy. <i>PLoS ONE</i> , 2016, 11, e0161878.	1.1	8
101	Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 9576-9585.	0.8	19
102	Establishment of an integrated model incorporating standardised uptake value and N-classification for predicting metastasis in nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 13612-13620.	0.8	18
103	Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study. <i>Oncotarget</i> , 2016, 7, 16806-16817.	0.8	9
104	Primary tumor inflammation in gross tumor volume as a prognostic factor for nasopharyngeal carcinoma patients. <i>Oncotarget</i> , 2016, 7, 14963-14972.	0.8	4
105	Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensitymatched analysis. <i>Oncotarget</i> , 2016, 7, 14973-14982.	0.8	21
106	Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: Defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy. <i>Scientific Reports</i> , 2015, 5, 16664.	1.6	34
107	Prognostic value of parotid lymph node metastasis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. <i>Scientific Reports</i> , 2015, 5, 13919.	1.6	10
108	Dose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma. <i>Scientific Reports</i> , 2015, 5, 13525.	1.6	14

#	ARTICLE	IF	CITATIONS
109	Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: a retrospective analysis. <i>BMC Cancer</i> , 2015, 15, 709.	1.1	29
110	Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. <i>Journal of Translational Medicine</i> , 2015, 13, 364.	1.8	67
111	Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone. <i>BMC Cancer</i> , 2015, 15, 930.	1.1	6
112	Dosimetric benefit to organs at risk following margin reductions in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. <i>Chinese Journal of Cancer</i> , 2015, 34, 189-97.	4.9	12
113	CXCL12 genetic variants as prognostic markers in nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 2835.	1.0	12
114	Clinical Outcomes of Volume-Modulated Arc Therapy in 205 Patients with Nasopharyngeal Carcinoma: An Analysis of Survival and Treatment Toxicities. <i>PLoS ONE</i> , 2015, 10, e0129679.	1.1	20
115	Incidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0131284.	1.1	4
116	Significant Prognostic Impact of Chemoradiotherapy-Induced Hemoglobin Decrease on Treatment Outcomes of Nasopharyngeal Carcinoma. <i>Journal of Cancer</i> , 2015, 6, 502-510.	1.2	10
117	Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials. <i>Journal of Cancer</i> , 2015, 6, 883-892.	1.2	68
118	Prognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: a retrospective study of 541 cases. <i>Scientific Reports</i> , 2015, 5, 12242.	1.6	51
119	Comorbidity predicts poor prognosis in nasopharyngeal carcinoma: Development and validation of a predictive score model. <i>Radiotherapy and Oncology</i> , 2015, 114, 249-256.	0.3	21
120	Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials. <i>Radiotherapy and Oncology</i> , 2015, 116, 157-166.	0.3	24
121	Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial. <i>Scientific Reports</i> , 2015, 5, 12502.	1.6	4
122	Comparison of the treatment outcomes of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension. <i>Radiotherapy and Oncology</i> , 2015, 116, 167-173.	0.3	14
123	Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2015, 15, 429.	1.1	13
124	Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact. <i>PLoS ONE</i> , 2015, 10, e0136752.	1.1	19
125	Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis. <i>Oncotarget</i> , 2015, 6, 29311-29323.	0.8	37
126	Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2014, 9, e110765.	1.1	31



#	ARTICLE	IF	CITATIONS
127	Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 110, 390-397.	0.3	126
128	Friend Leukemia Virus Integration 1 Expression Has Prognostic Significance in Nasopharyngeal Carcinoma. <i>Translational Oncology</i> , 2014, 7, 493-502.	1.7	12
129	Is replacement of the supraclavicular fossa with the lower level classification based on magnetic resonance imaging beneficial in nasopharyngeal carcinoma?. <i>Radiotherapy and Oncology</i> , 2014, 113, 108-114.	0.3	26
130	Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma treated with intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 110, 404-408.	0.3	24
131	The Pretreatment Albumin to Globulin Ratio Has Predictive Value for Long-Term Mortality in Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2014, 9, e94473.	1.1	99
132	Diabetes, Prediabetes and the Survival of Nasopharyngeal Carcinoma: A Study of 5,860 Patients. <i>PLoS ONE</i> , 2014, 9, e111073.	1.1	7
133	Proposed Lymph Node Staging System Using the International Consensus Guidelines for Lymph Node Levels Is Predictive for Nasopharyngeal Carcinoma Patients From Endemic Areas Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 249-256.	0.4	65
134	Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. <i>Cancer</i> , 2013, 119, 2230-2238.	2.0	144
135	Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 163-171.	5.1	468
136	The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. <i>Radiotherapy and Oncology</i> , 2012, 104, 331-337.	0.3	104
137	Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation. <i>Chinese Journal of Cancer</i> , 2012, 31, 579-587.	4.9	94
138	The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma. <i>Cancer</i> , 2009, 115, 680-688.	2.0	118
139	Re-Evaluation of 6th Edition of AJCC Staging System for Nasopharyngeal Carcinoma and Proposed Improvement Based on Magnetic Resonance Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1326-1334.	0.4	236
140	Extension of Local Disease in Nasopharyngeal Carcinoma Detected by Magnetic Resonance Imaging: Improvement of Clinical Target Volume Delineation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 742-750.	0.4	95
141	Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by magnetic resonance imaging. <i>Cancer</i> , 2008, 113, 347-354.	2.0	119
142	Preliminary Results of a Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma in Endemic Regions of China. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1356-1364.	0.4	207
143	Disparities in positive results and dissemination of randomized controlled trials in immuno-oncology. <i>International Reviews of Immunology</i> , 0, , 1-10.	1.5	0